ArticleMedicine2016
Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case report.
Article in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.Cancer biology & medicine · 2020Trial
- Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection.Cancers · 2024Review
- Efficacy and safety of apatinib in advanced refractory soft tissue sarcoma and association with histologic subtypes: a multicenter retrospective study.Annals of translational medicine · 2022Article
- Concurrent minimal change disease and retroperitoneal liposarcoma successfully treated by tumor resection and steroid therapy.CEN case reports · 2021Article
- Anti-Tumor Effect of Apatinib and Relevant Mechanisms in Liposarcoma.Frontiers in oncology · 2021Article
- Liposarcoma: Advances in Cellular and Molecular Genetics Alterations and Corresponding Clinical Treatment.Journal of Cancer · 2020Review
- Efficacy and Safety of Apatinib in the Treatment of Postoperative Recurrence of Fibrosarcoma.OncoTargets and therapy · 2020Article
- Pulmonary metastases of fibrosarcomatous dermatofibrosarcoma protuberans respond to apatinib-based angiogenesis and chemotherapy: a case report.Annals of translational medicine · 2019Article
- Efficacy and safety of apatinib in advance osteosarcoma with pulmonary metastases: A single-center observational study.Medicine · 2018Observational
- Apatinib as targeted therapy for sarcoma.Oncotarget · 2018Review
- Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study.Cancer biology & therapy · 2018Observational
- The efficacy and safety of apatinib in Ewing's sarcoma: a retrospective analysis in one institution.Cancer management and research · 2018Article
- Treatment of medullary thyroid carcinoma with apatinib: A case report and literature review.Medicine · 2017Review
- Clinicopathological characteristics and experience in the treatment of giant retroperitoneal liposarcoma: A case report and review of the literature.Cancer biology & therapy · 2017Review
- Apatinib inhibits VEGFR-2 and angiogenesis in anOncotarget · 2017Article
- Article
- Advanced alveolar soft part sarcoma responds to apatinib.Oncotarget · 2017Article
- Case report of aOncoTargets and therapy · 2017Article
- Recent translational research into targeted therapy for liposarcoma.Stem cell investigation · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMyxoid/round cell liposarcoma is the second most common subtype of liposarcoma. Chemotherapy and radiotherapy have a limited efficacy for treating advanced myxoid/round cell liposarcoma, with relatively serious side effects. CASE PRESENTATION: We herein present a 68-year-old Chinese woman initially diagnosed with advanced multiple intra-abdominal and pelvic round cell liposarcoma.She refused to receive cytotoxic chemotherapy and received apatinib as the first-line therapy, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 that has been used in the treatment of patients with metastatic gastric cancer who progressed with 2 or more chemotherapy regimens. This patient was partially responsive to apatinib with a dose of 500 mg daily. No serious drug-related side effects were observed.
conclusionOur findings indicate that some cases of liposarcoma may be responsive to antiangiogenic agent apatinib. Randomized clinical studies are needed to further confirm the efficacy and safety of apatinib in the clinical treatment of liposarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.